checkmate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
Published 6 years ago • 623 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
2:30
checkmate 214 trial update
-
4:39
nivolumab and ipilimumab for metastatic kidney cancer
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
3:21
cabosun trial: cabozantinib vs sunitinib for renal cell carcinoma
-
5:06
phase 3 checkmate - 214
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
1:56
checkmate 9er: arcc patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
2:13
treating advanced renal-cell carcinoma
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
2:08
nivolumab with ipilimumab for mrcc
-
3:19
radvax: nivolumab / ipilimumab with sbrt for metastatic renal cell carcinoma
-
3:09
should sunitinib still be used in the treatment of metstatic kidney cancer?
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
5:26
mrcc: impact of cabosun and checkmate-214
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc